East Bay drug maker to appeal FDA rejection of kidney treatment
November 04, 2021 at 18:01 PM EDT
The appeal, to be filed yeet this year, did little to change investors' minds on the fate of the drug — the stock gained just a penny on the day, then shed that penny in after-hours trading.
